Legal & General Group
UNCY icon

Legal & General Group’s Unicycive Therapeutics UNCY Stock Holding History

Legal & General Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1K Buy
+2,365
New +$17.4K ﹤0.01% 3295

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Legal & General Group's UNCY Position: Q2 2026 in Review

Legal & General Group opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 2,365 shares worth $11.1K. The stake represents ﹤0.01% of the portfolio and ranks #3295 among its holdings.

80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Legal & General Group held 2,365 shares of Unicycive Therapeutics worth $11.1K as of Q2 2026.
  • Unicycive Therapeutics was a new Legal & General Group position in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3295 holding.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.